Retatrutides ~24.2% (48 wk, 12 mg monotherapy) and cagrilintides ~10.8% (26 wk, 4.5 mg monotherapy) differ in duration and dose, and cagrilintides strongest data are combination (CagriSema) data
BPC-157 administration (10 mcg/kg or 10 ng/kg intraperitoneally, or 0.16 mcg/ml in drinking water) produced recovery of esophagitis lesions both macroscopically and microscopically
For example, around the mouth and to support and smooth out lines and wrinkles
Disclaimer: The information contained in this website is only for general interest and informational purposes, and is in no way meant to be used to diagnose or prescribe medication or supplementation of any kind to treat any illnesses or symptoms of illnesses
Signs You May Have Low Vitamin B12 Tingling or numbness in the feet Burning or stabbing nerve pain Fatigue, and weakness while walking Balance problems Blood testing is recommended before treatment where possible
BPC-157 has no approved therapeutic indication in humans and is not recognized as a medicine, supplement, or drug by Health Canada